Loading...
Found 8 results for monika-fischer-md
A listing of monika-fischer-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
M
Monika Fischer, MD
What is the purpose of this study?The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active …
Standardized Microbiota Transplant Therapy in Crohn's Disease - Pilot Trial
M
Monika Fischer, MD
Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation (FMT) for the treatment of recurrent …
Fecal Microbiota Transplant (FMT) National Registry
M
Monika Fischer, MD
What is the purpose of this study?This is a national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness. This registry will prospectively enroll 4,000 patients who undergo FMT at 75 sites throughout North America. This …
A Phase 2A Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease
M
Monika Fischer, MD
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may …
A Phase 2B/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
M
Monika Fischer, MD
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).THIS STUDY IS ENROLLING BY INVITATION ONLY
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
M
Monika Fischer, MD
The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes …
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program toEvaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to SeverelyActive Crohn's Disease
M
Monika Fischer, MD
What is the purpose of this study?The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study …
A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
M
Monika Fischer, MD
The purpose of this study is to assess the efficacy and safety of RO7790121 (formerly PF-06480605 and RVT-3101) in patients with moderately to severely active Crohn's disease (CD). RO7790121 is a fully human neutralizing immunoglobulin G monoclonal antibody (mAb) against tumor necrosis factor-like ligand 1A (TL1A). TL1A plays a central …
Please choose between Voice or SMS based delivery of verification code
or